Tag: AIPT

Helomics Holding Corporation, predicted to generate approximately $3.2 million in revenues by the end of 2018 MINNEAPOLIS, Aug. 14, 2018 ...

Precision Therapeutics Investee, Helomics Corporation, Launches Precision Oncology Insights Platform

MINNEAPOLIS, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”), a company focused on applying artificial ...

Precision Therapeutics Receives Approval of Delisting Request from German Stock Exchange

MINNEAPOLIS, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”), a company focused on applying artificial ...

Precision Therapeutics Launches New Website

MINNEAPOLIS, May 31, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence ...

Video News on Precision Therapeutics Inc (Nasdaq: AIPT) – Company Projects Meaningful STREAMWAY System Sales in Europe in the Second Half of 2018

Video News On PRECISION THERAPEUTICS, INC. - NASDAQ: AIPT https://youtu.be/G7Vc44qfBMQ About the STREAMWAY System Skyline's revolutionary, FDA-cleared STREAMWAY ...

Precision Therapeutics Projects Meaningful STREAMWAY System Sales in Europe in the Second Half of 2018

MINNEAPOLIS, May 10, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence ...

Precision Therapeutics to Hold Business Update Conference Call on May 15, 2018

MINNEAPOLIS, May 08, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence ...

Precision Therapeutics, Inc. Signs Letter of Intent to Purchase Remainder of Helomics Corporation Shares

MINNEAPOLIS, (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine ...

Precision Therapeutics, Inc. Engages Richard Gabriel to Drive Business Development Strategy for its TumorGenesis Subsidiary

Richard Gabriel, BS, MBA is a board member of Precision Therapeutics and spearheaded the licensing of new technologies for 3D ...

Precision Therapeutics Reports Fiscal Year 2017 Financial Results

Company reports strengthening STREAMWAY® System sales and new strategic focus on the emerging precision medicine market MINNEAPOLIS, April 02, 2018 ...

Precision Therapeutics Announces Record STREAMWAY® System Sales in the First Three Months of 2018

Sixteen STREAMWAY Systems sold in Q1 2018, compared with five units sold in Q4 2017 and three sold in Q1 ...

Precision Therapeutics to Hold Business Update Conference Call on April 2, 2018

MINNEAPOLIS, (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), formerly Skyline Medical, a company focused on applying artificial intelligence ...

Precision Therapeutics Subsidiary, TumorGenesis, Announces License Agreement with CellBridge Incorporated

MINNEAPOLIS, March 21, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), formerly Skyline Medical, announced today that its ...

Precision Therapeutics Subsidiary, TumorGenesis, Announces License Agreement with 48Hour Discovery

MINNEAPOLIS, March 15, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), formerly Skyline Medical, announced today that its ...

Precision Therapeutics Subsidiary, TumorGenesis, Announces License Agreement with SyntArray, LLC

MINNEAPOLIS, March 13, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), formerly Skyline Medical, announced today that its ...

Precision Therapeutics Forms TumorGenesis Inc. Subsidiary to Focus on the Next Generation of Patient Derived Tumor Models